Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
535 JPY | +0.19% | -5.15% | -60.00% |
2023 | SUSMED,Inc.(TSE:4263) added to S&P Global BMI Index | CI |
2022 | Walgreens Boots Alliance, Inc. Joins Sustainable Medicines Partnership | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Sector: IT Services & Consulting
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-60.00% | 5.96Cr | - | ||
-12.08% | 19TCr | A- | ||
+2.29% | 17TCr | B+ | ||
+2.88% | 15TCr | B- | ||
+5.86% | 10TCr | A- | ||
+11.32% | 8.1TCr | A- | ||
+34.39% | 7.97TCr | C- | ||
-7.97% | 7.06TCr | A | ||
-17.40% | 5.38TCr | C | ||
-9.09% | 4.28TCr | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4263 Stock
- Ratings SUSMED,Inc.